Summary of DIATEC Trial: Improving In-Hospital Diabetes Management
Background
Up to 20% of hospitalized patients have diabetes, leading to increased mortality, morbidity, and hospital stays. The DIATEC trial aims to improve in-hospital diabetes management strategies.
Methods
The trial is a two-armed, two-site, prospective randomised open-label blinded endpoint (PROBE) trial. Non-critically ill hospitalised patients with type 2 diabetes (N = 166) are recruited. Patients are monitored by point-of-care (POC) glucose testing and managed by in-hospital diabetes teams. In one arm, patients are additionally monitored by continuous glucose monitoring (CGM) viewed by the in-hospital diabetes teams only. Both arms have operational algorithms to titrate insulin.
Discussion
The DIATEC trial will demonstrate the effects of in-hospital CGM handled by diabetes teams in non-critically ill patients with type 2 diabetes. It aims to identify which patients will benefit from CGM and in-hospital diabetes teams compared to POC glucose testing, providing essential information to optimize healthcare resources.
Trial Registration
Prospectively registered at ClinicalTrials.gov with identification number NCT05803473 on March 27th, 2023.
Clinical Trials and AI-Driven Solutions
Clinical trials are crucial for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research into an easily accessible knowledge base for clinicians, extending the benefits of clinical trials into everyday medical practice.
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
By using AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper routines. Learn more about how we can help at aidevmd.com.
